Prelude Therapeutics Gets FDA Green Light for Groundbreaking Blood Cancer Treatment

Prelude Therapeutics receives FDA clearance to begin testing PRT12396, a targeted therapy for myeloproliferative neoplasms affecting thousands of patients.